Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by E-DA Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
E-DA Hospital
ClinicalTrials.gov Identifier:
NCT01182259
First received: August 13, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted
  Purpose

Tuberculosis remains one of the largest health problems in the world today. Multidrug therapy is necessary to cure tuberculosis patients and to prevent the selection of drug-resistant mutants, however, which may increase the incidence of side effects during the course of treatment. These side effects may be mild as well as fatal. A severe side effect against one of the anti-TB drugs, which influences drug compliance, may lead to the discontinuation of that drug. At the same time, the risk of treatment failure and relapse are higher. Therefore monitoring the rate of anti-TB drugs induced adverse effects and the related risk factors is crucial. Awareness of the risk groups may decrease the incidence of serious drug-related side effects and medical cost.

The fixed-dose combinations (FDCs) of tablets against tuberculosis is now being recommended by WHO, which simplify the prescription of drugs and prevent the development of drug resistance. However, the FDC regimen is not consistent with the dosages that are usually given, the higher risk of drug toxicity and adverse reactions should be considered. To our knowledge, there was no report to assess the adverse effects of FDC anti-TB drugs in Taiwan. The aim of the present study is to investigate the current incidence of side effects and the risk factors related to FDC drugs for side effects during the initial phase of therapy.


Condition
Tuberculosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by E-DA Hospital:

Estimated Enrollment: 200
Study Start Date: October 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Newly diagnosed TB patient in E-DA hospital

Criteria

Inclusion Criteria:

  1. Newly diagnosed pulmonary TB and extrapulmonary TB patients
  2. No previous anti-TB drugs treatment
  3. Age more than 18years old

Exclusion Criteria:

  1. Expected life < 6months
  2. Baseline AST and ALT > 3 fold upper limit of normal (ULN) or total bilirubin>2mg/dl
  3. Age less than 18years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01182259

Contacts
Contact: Jiun-Ting Wu, MD 886-7-615-0011 ext 2980 ed103621@edah.org.tw

Locations
Taiwan
E-DA hospital Recruiting
Kaohsiung, Taiwan
Contact: Chien-Tung Chiu    886-7-615-0011 ext 2980    chiuct168@gmail.com   
Principal Investigator: Yuan-Kun Tu, MD         
Sponsors and Collaborators
E-DA Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01182259     History of Changes
Other Study ID Numbers: JTWu002
Study First Received: August 13, 2010
Last Updated: August 13, 2010
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on November 25, 2014